Generic drug makers are hailing the planned creation of a new government fund designed to support the industry’s manufacturing infrastructure,…
COLUMN
How Can You Improve Field Force Productivity in the Age of Digital? Omnichannel Excellence and the Importance of a Strong “Middle Layer”
Introduction In my first column, I introduced four key lessons learnt from ongoing commercial transformations at pharma companies in Japan, based on a recent survey with 150 pharma leaders in Japan and our own experience as strategic transformation advisor. In…
To read the full story
Related Article
COLUMN
- A Conversation with Bill Schuster: Navigating the Complexities of Healthcare Leadership
January 24, 2025
- A Conversation with James Feliciano: Navigating the Complexities of the Japanese Pharmaceutical Industry
December 23, 2024
- How to Be a Country Manager
November 29, 2024
- Elevating Leadership: Insights from Japan’s Healthcare Sector
October 23, 2024
- 6 Tips for Motivating and Engaging Current Employees
September 30, 2024
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…